Tumor Lysis Prophylaxis: When the Best Drug for the Job Is Never an Option
A G6PD result takes the best tumor-lysis prophylaxis off the table absolutely, not conditionally. What is left has to be assembled from weaker components, and started before a rapidly growing lymphoma finishes making the decision for everyone.
K.O., a 41-year-old man, presented to urgent care with drenching night sweats and a rapidly enlarging neck mass that had, by his own account, visibly grown over the preceding two weeks. Biopsy confirmed a high-grade B-cell lymphoma, and staging labs showed an LDH nearly four times the upper limit of normal, a uric acid already at 8.9 mg/dL, and a creatinine sitting at the top of its reference range — a combination that places him in the high tumor lysis risk category before a single dose of chemotherapy, and, more to the point, indicates the process has begun spontaneously. The bulky abdominal adenopathy is turning over fast enough to raise his urate on its own. Pre-treatment screening, run routinely before rasburicase is considered in any high-risk patient, returned a G6PD level in the deficient range — the finding rasburicase's own boxed warning names as a contraindication rather than a caution.
Rasburicase is, in ordinary circumstances, clearly the more effective prophylaxis for a tumor lysis risk this high — it degrades uric acid directly rather than only blocking its production the way allopurinol does. But that degradation reaction generates hydrogen peroxide as an unavoidable byproduct, and red blood cells lacking functional glucose-6-phosphate dehydrogenase can't mount the glutathione-based defense needed to clear that peroxide load, resulting in severe hemolysis. There is no dose reduction or monitoring plan that touches this mechanism. His G6PD status does not move the rasburicase decision toward caution; it removes the drug, which leaves the team building prophylaxis for a high-risk patient out of the moderate-risk toolkit. That would be manageable if time were available, and the awkward feature of his case is that it is not: allopurinol blocks new urate production but does nothing to the 8.9 already circulating, and it works best given a day or two ahead of chemotherapy — a day or two his neck mass has spent the last fortnight demonstrating it will use.
Inpatient oncology, TLS prophylaxis planning
This needs to be stated as an absolute, not a caution, and the label states it that way too: rasburicase carries a boxed warning for hemolysis in G6PD deficiency, and it is listed as a contraindication rather than a warning. The mechanism is why — the enzyme generates hydrogen peroxide as it degrades uric acid, and G6PD-deficient red cells cannot mount the glutathione-dependent defense to clear it. No dose adjustment or monitoring protocol changes that. It is off the table entirely, however high his risk category runs.
Accepting that fully, the question becomes how to make allopurinol-based prophylaxis do as much work as it can for a risk this high. Coiffier's tumor-lysis guidance is built for exactly this situation — aggressive IV hydration starting now, allopurinol begun 24 to 48 hours ahead of chemotherapy where clinical status allows the delay, and laboratory monitoring frequent enough to catch a rising potassium or phosphate before it becomes a rhythm problem. It is a materially less potent safety net than rasburicase would have been, but it is not a passive one.
Calling allopurinol 'less effective' undersells what aggressive hydration adds on top of it — the two together aren't just a weaker version of rasburicase, they're a genuinely different strategy that can still control this if we start early enough.
I'd flag the other side of 'start early enough' — his mass has visibly grown over two weeks and he's drenching through his sheets at night. Every day spent optimizing hydration and pre-loading allopurinol before chemotherapy starts is a real day of continued disease growth and symptom burden, not a free delay. I'm not arguing to skip the optimization — I'm arguing it needs to happen on the fastest timeline that's actually safe, not the most thorough one that's theoretically possible.
Agreed: allopurinol and aggressive hydration started with a 36-hour pre-chemotherapy window, balancing prophylaxis optimization against his rapidly progressive, symptomatic disease.
Not agreed: exactly how long a delay before chemotherapy was appropriate — the emergency medicine physician's push for the shortest safe window and the hematologist-oncologist's preference for the full 48 hours where possible were not fully reconciled; 36 hours was accepted as a working compromise for this admission, not a resolved answer for how this tradeoff should be weighed in a future, more urgent case.